![]() |
JOURNAL TOOLS |
Opzioni di pubblicazione |
eTOC |
Per abbonarsi |
Sottometti un articolo |
Segnala alla tua biblioteca |
ARTICLE TOOLS |
Estratti |
Permessi |
Share |


I TUOI DATI
I TUOI ORDINI
CESTINO ACQUISTI
N. prodotti: 0
Totale ordine: € 0,00
COME ORDINARE
I TUOI ABBONAMENTI
I TUOI ARTICOLI
I TUOI EBOOK
COUPON
ACCESSIBILITÀ
REVIEWS NEUROENDOCRINE UPDATE AND METABOLIC THERAPY
The Quarterly Journal of Nuclear Medicine and Molecular imaging 2010 February;54(1):37-51
Copyright © 2010 EDIZIONI MINERVA MEDICA
lingua: Inglese
Dosimetry for treatment with radiolabelled somatostatin analogues. A review
Cremonesi M. 1, Botta F. 1, Di Dia A. 1, Ferrari M. 1, Bodei L. 2, De Cicco C. 2, Rossi A. 1, Bartolomei M. 3, Mei R. 2, Severi S. 4, Salvatori M. 5, Pedroli G. 1, Paganelli G. 2 ✉
1 Medical Physics, European Institute of Oncology, Milan, Italy; 2 Nuclear Medicine Divisions, European Institute of Oncology, Milan, Italy; 3 Nuclear Medicine Institute, Ospedale Bufalini, Cesena, Italy; 4 Division of Nuclear Medicine, Scientific Institute for the study and treatment of tumors, Meldola, Italy; 5 Institute for Nuclear Medicine, S. Cuore Catholic University, Rome, Italy
Peptide Receptor Radionuclide Therapy (PRRT) has proven its efficacy in the treatment of neuroendocrine and other somatostatin receptor expressing tumours (SR-tumours). Several clinical trials have confirmed that adverse effects are represented by possible renal impairment, which is the major concern, and low but not absent hematological toxicity. High kidney irradiation is a constant, despite the sparing of dose obtained by renal protectors. Hematological toxicity, although low, needs to be monitored. The clinical and dosimetry results collected in more than a decade have recognized weak points to unravel, increased knowledge, offering new views. When planning therapy with radiopeptides, the large patients’ variability as for biodistribution and tumour uptake must be taken into account in order to tailor the therapy, or at least to avoid foreseeable gross treatments. Reliable and personalized dosimetry is more and more requested. This paper reviews through the literature the methods to study the biokinetics, the dosimetry outcomes, some clue information and correlations obtained once applying the radiobiological models. Special focus is given on recent improvements and indications for critical organ protection that light up challenging perspectives for PRRT.